| Similar Articles |
|---|
 |
The Motley Fool
August 11, 2009
Jeff Fischer |
Profit Whichever Way a Stock Goes You can buy straddles to profit from volatility.   |
The Motley Fool
January 12, 2010
Jeff Fischer |
Bull or Bear, Profit Anyway Everyone can make money in 2010. |
The Motley Fool
May 21, 2010
Jeff Fischer |
Use Options to Protect, Hedge, and Gain They're not just for speculators. |
The Motley Fool
December 14, 2010
Brian Orelli |
3 Ways to Play Biotech With Options Are you looking for a way for options to help you decrease the risk of investing in biotechnology? Then read on. |
The Motley Fool
December 8, 2010
Brian Orelli |
Up 100% With Room to Fly Orexigen gets a positive FDA panel nod. |
The Motley Fool
May 27, 2008
Brian Orelli |
Livin' la Vivus Loca Irrational Exuberance for Vivus' Lead Drug Candidate? |
The Motley Fool
April 30, 2007
Mike Havrilla |
VIVUS Revives Investor Interest New drugs with huge markets could keep shares of VIVUS on their upward trajectory. |
The Motley Fool
July 14, 2010
Luke Timmerman |
Vivus Faces Turning Point Tomorrow Thursday's the big day. All eyes will be on Vivus and the FDA's decision on their new obesity drug |
The Motley Fool
September 9, 2009
Brian Orelli |
Weight Down. Stock Price Up. Really Up. Positive phase 3 trials will do that for VIVUS' anti-obesity drug, Qnexa |
The Motley Fool
April 1, 2008
Brian Lawler |
VIVUS' New Old Drugs The small company finds plenty of help as it tries to get its anti-obesity drug to market. |
The Motley Fool
July 16, 2010
Luke Timmerman |
Vivus Obesity Drug Shot Down by FDA Panel Vivus suffered a setback today at an important meeting for the future of obesity drug development, with implications for Arena Pharmaceuticals and Orexigen Therapeutics. |
The Motley Fool
December 12, 2008
Brian Orelli |
The Skinny on the Latest Drug Trial VIVUS' obesity treatment data looks good, but will its drug be a marketing success? |
The Motley Fool
May 4, 2011
Brian Orelli |
VIVUS Unveils Its Obesity Plans Investors are getting fat on the news that VIVUS has a plan, and a backup plan, to get its obesity drug Qnexa on the market. |
The Motley Fool
December 11, 2009
James Early |
What to Do Now? I'll Tell You. The market can't make up its mind -- but you can -- if you try one simple trick from the professional investors' handbook. |
The Motley Fool
February 12, 2010
Brad Hessel |
So Far, It's Not Like the 1930s Stock market volatility declines -- again. |
The Motley Fool
July 13, 2010
Brian Orelli |
A Triple Delight: 3 Stocks All Up More Than 10% What's good for the obese goose is good for the gander when it comes to new drug treatments for losing weight. |
The Motley Fool
September 21, 2010
Brian Orelli |
Double-Digit Weight Loss, Double-Digit Share Increase Vivus is down, but apparently not out. |
The Motley Fool
May 25, 2011
Brian Orelli |
Satisfying Clinical Trial Straightens Up Shares VIVUS' erectile dysfunction drug avanafil works. |
The Motley Fool
September 16, 2011
Brian Orelli |
A Shrinking Obesity Market VIVUS figures some sales are better than none for its obesity drug Qnexa. |
The Motley Fool
January 9, 2012
Brian Orelli |
Don't Believe This Company's Warning VIVUS' news is great news. |
The Motley Fool
April 5, 2011
Brian Orelli |
Obese Expectations Trump Great Data Sorry VIVUS and Orexigen, you're still not going to get your drugs approved quickly. |
The Motley Fool
November 18, 2009
Brian Orelli |
VIVUS Gets a Spark A new erectile-dysfunction drug shows promise. |
The Motley Fool
July 16, 2010
Tom Hughes |
Lessons Learned About the Outlook for New Obesity Drug Approval The recent FDA advisory committee meeting on Vivus' weight loss pill proved to us, once again, how incredibly difficult it is to successfully develop and register new drugs for obesity. |
The Motley Fool
October 26, 2006
Dan Caplinger |
Volatility: Friend or Foe? By being aware of volatility and taking steps to reduce it, while also making the most of the opportunities it brings, you can not only improve your investment returns, but also avoid the anxiety of dramatic movements in your net worth. |
Financial Advisor
February 2012
Somnath Basu |
Making Money, Getting It Right The greatest fallacy is that you have to find the winners to make money. But really you need to find the winners, losers and sideways movers. |
Financial Planning
May 1, 2013
Allan S. Roth |
Are Stocks Really More Volatile Now? The stock market has been more erratic in recent years - but not as much as you might think. |
Registered Rep.
December 31, 2012
Brad Zigler |
Eight Novel ETFs Looking to Break Into 2013 These proposed funds run the gamut from simple to complex. All are intriguing. |
Registered Rep.
January 23, 2013
Brad Zigler |
"Hedge" Is the Word for 2013 In 2013, the market for alternative investment exchange-traded products seems to revolve around one word. That word is "hedge." Judging by their proportion of regulatory filings and launches last quarter, product sponsors are keen on risk-controlled equity and bond plays. |
The Motley Fool
September 21, 2011
Brian Orelli |
Obesity-Drug Makers Stop Getting Bullied The drugs are still relative long shots being developed by companies that may have to raise more cash between now and an approval. |
